The biotech industry in South Korea has made notable achievements in treating MASH. Many pharmaceutical companies have failed in clinical trials to develop a treatment for MASH due to its complex pathogenesis. As the first treatment for MASH has been approved, the industry draws attention to the success of the commercialization of other new drug candidates of various pharmaceutical companies that entered clinical trials in South Korea.

On July 11th, the current trend in the MASH treatment development was discussed during the Bioplus-Interphex Korea 2024 (BIX 2024), sponsored by the Korea Biotechnology Industry Organization (Korea Bio) and RX Korea. MASH was previously known as Non-Alcoholic Steatohepatitis